Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

n.v. organon, oss array - 14895 sodnÁ sŮl montelukastu - potahovaná tableta - 10mg - montelukast

USA - engelsk - NLM (National Library of Medicine)

merck sharp & dohme corp. - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 4 mg - singulair® is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. singulair is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. because the benefits of singulair may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see warnings and precautions (5.1)] , reserve use for patients who have an inadequate response or intolerance to alternative therapies. singulair is not indicated for the treatment of an acute asthma attack. singulair is contraindicated in patients with hypersensitivity to any of its components. risk summary available data from published prospective and retrospective cohort studies over decades with montelukast use in pregnant women have not estab

USA - engelsk - NLM (National Library of Medicine)

organon llc - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - singulair® is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. singulair is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. because the benefits of singulair may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see warnings and precautions (5.1)] , reserve use for patients who have an inadequate response or intolerance to alternative therapies. singulair is not indicated for the treatment of an acute asthma attack. singulair is contraindicated in patients with hypersensitivity to any of its components. risk summary available data from published prospective and retrospective cohort studies over decades with montelukast use in pregnant women have not estab

USA - engelsk - NLM (National Library of Medicine)

rebel distributors corp - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 5 mg - singulair1 is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. registered trademark of merck sharp & dohme corp., a subsidiary of merck & co., inc. copyright © 1998-2010 merck sharp & dohme corp., a subsidiary of merck & co., inc. all rights reserved singulair is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 15 years of age and older. singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. hypersensitivity to any component of this product. pregnancy category b: there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, singulair should be used during pregnancy only if clearly needed. teratogenic effect: no teratogenicity was observed in rats and rabbits at doses approximate

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 4 mg - singulair® is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. singulair is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 15 years of age and older. singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. hypersensitivity to any component of this product. pregnancy category b: there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, singulair should be used during pregnancy only if clearly needed. teratogenic effect: no teratogenicity was observed in rats and rabbits at doses approximately 100 and 110 times, respectively, the maximum recommended daily oral dose in adults based on aucs [see nonclinical toxicology (13.2)] . during worldwide marketing experience, congenital limb

Israel - engelsk - Ministry of Health

organon pharma israel ltd., israel - montelukast as sodium - granules - montelukast as sodium 4 mg - montelukast - singulair is indicated in adult and pediatric patients 12 months of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin - sensitive asthmatic patients, and the prevention of exercise - induced bronchoconstriction. singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma.singulair and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability.

Israel - engelsk - Ministry of Health

organon pharma israel ltd., israel - montelukast as sodium - chewable tablets - montelukast as sodium 5 mg - montelukast - montelukast - singulair 5 mg is indicated in adult and pediatric patients 6 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms of the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. singulair and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.because the benefits of singulair may not outweigh the risk of neuropsychiatric symptoms in patients with seasonal rhinitis [see warnings and precautions (5.1)], reserve use for patients who have an intolerance to alternative therapies.

Israel - engelsk - Ministry of Health

organon pharma israel ltd., israel - montelukast as sodium - tablets - montelukast as sodium 10 mg - montelukast - montelukast - singulair 10 mg is indicated in adult and adolescents 15 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms of the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. singulair and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.because the benefits of singulair may not outweigh the risk of neuropsychiatric symptoms in patients with seasonal rhinitis [see warnings and precautions (5.1)], reserve use for patients who have an intolerance to alternative therapies.

Israel - engelsk - Ministry of Health

organon pharma israel ltd., israel - montelukast as sodium - chewable tablets - montelukast as sodium 4 mg - montelukast - montelukast - singulair is indicated in pediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. singulair and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability.singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.because the benefits of singulair may not outweigh the risk of neuropsychiatric symptoms in patients with seasonal rhinitis [see warnings and precautions (5.1)], reserve use for patients who have an intolerance to alternative therapies.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - montelukast sodium, quantity: 4.16 mg (equivalent: montelukast, qty 4 mg) - tablet, chewable - excipient ingredients: aspartame; mannitol; iron oxide red; hyprolose; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; flavour - prophylaxis and treatment of chronic asthma in adults and children two years of age and over. symptomatic treatment of seasonal allergic rhinitis